MENU
IBRN
ETF ticker: NYSE ARCA
PRICE
CHANGE
NET ASSETS

IBRN stock forecast, quote, news & analysis

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U... Show more

Category: #Health
IBRN
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for IBRN with price predictions
Oct 02, 2026

IBRN in downward trend: price dove below 50-day moving average on September 08, 2026

IBRN moved below its 50-day moving average on September 08, 2026 date and that indicates a change from an upward trend to a downward trend. In 32 of 33 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 31, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IBRN as a result. In 63 of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.

The Moving Average Convergence Divergence Histogram (MACD) for IBRN turned negative on August 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In 32 of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at 80%.

The 10-day moving average for IBRN crossed bearishly below the 50-day moving average on September 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBRN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for IBRN entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 18 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +1.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where IBRN advanced for three days, in 175 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

IBRN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Biogen (NASDAQ:BIIB), Sarepta Therapeutics (NASDAQ:SRPT).

Industry description

The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience. The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index.

Market Cap

The average market capitalization across the iShares Neuroscience and Healthcare ETF (IBRN) ETF is 4.31B. The market cap for tickers in the group ranges from 89.24M to 60.12B. ARGX holds the highest valuation in this group at 60.12B. The lowest valued company is CGTX at 89.24M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Neuroscience and Healthcare ETF (IBRN) ETF was -2%. For the same ETF, the average monthly price growth was -18%, and the average quarterly price growth was -2%. ANNX experienced the highest price growth at 15%, while CLPT experienced the biggest fall at -27%.

Volume

The average weekly volume growth across all stocks in the iShares Neuroscience and Healthcare ETF (IBRN) ETF was 6%. For the same stocks of the ETF, the average monthly volume growth was 17% and the average quarterly volume growth was -26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 71
Price Growth Rating: 63
SMR Rating: 90
Profit Risk Rating: 86
Seasonality Score: -5 (-100 ... +100)
View a ticker or compare two or three
IBRN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com
IBRN in downward trend: price dove below 50-day moving average on September 08, 2026